![](https://img.einpresswire.com/small/546624/innorna-logo.jpeg)
Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN022 for the Treatment of Homocystinuria
UNITED STATES, July 9, 2024 /EINPresswire.com/ -- Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel RNA therapeutics, announced a significant milestone today. The U.S. Food and Drug …